Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices
Open Access
- 30 May 1991
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (22), 1532-1538
- https://doi.org/10.1056/nejm199105303242202
Abstract
The value of beta-adrenergic—antagonist drug therapy for the prevention of initial episodes of gastrointestinal bleeding in patients with cirrhosis and esophageal varices is uncertain, both positive and negative study results having been reported.This publication has 11 references indexed in Scilit:
- Propranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients: Final report of a multicenter randomized trialJournal of Hepatology, 1989
- Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosisJournal of Hepatology, 1988
- Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized studyHepatology, 1988
- Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal VaricesNew England Journal of Medicine, 1987
- Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleedingHepatology, 1987
- Pitfalls in studies of prophylactic therapy for variceal bleeding in cirrhoticsHepatology, 1986
- Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertensionAmerican Heart Journal, 1984
- Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.Gut, 1984
- The Effect of Propranolol on Portal Hypertension in Patients with Cirrhosis: A Hemodynamic StudyHepatology, 1982
- PROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION?The Lancet, 1980